Phion Therapeutics - Administration

Phion Therapeutics, a Belfast-based biotechnology company specializing in the development of ground-breaking nucleic acid vaccines and therapeutics, entered administration on 24 September.

Phion’s lead product is a therapeutic vaccine against HPV driven cancers and pipeline programs include therapeutic vaccines against ovarian cancer, prostate cancer, and a prophylactic vaccine against Crimean-Congo Haemorrhagic Fever.

The company has a number of patents relating to the innovative delivery system which aim to improve the effectiveness of vaccines and treatments by generating strong and lasting immune responses.

James Neill and John Donaldson of KPMG Ireland were appointed joint administrators.

Innovate UK Loans has a registered charge against the company.